Targeting DNA Repair in Cancer: Beyond PARP Inhibitors

Overview

Journal Cancer Discov

Specialty Oncology

Date 2016 Dec 23

PMID 28003236

Citations 301

Authors

Jessica S Brown

Brent OCarrigan

Stephen P Jackson

Timothy A Yap

Affiliations

Soon will be listed here.

Abstract

Significance: Various inhibitors of DDR components are in preclinical and clinical development. A thorough understanding of DDR pathway complexities must now be combined with strategies and lessons learned from the successful registration of PARP inhibitors in order to fully exploit the potential of DDR inhibitors and to ensure their long-term clinical success. Cancer Discov; 7(1); 20-37. ©2016 AACR.

Citing Articles

A prognostic model of lung adenocarcinoma constructed based on circadian rhythm genes and its potential clinical significance.

Fu C, Sun L, Feng C, Zhou T, Bi Y Front Oncol. 2025; 15:1464578.

PMID: 40040723 PMC: 11876053. DOI: 10.3389/fonc.2025.1464578.

Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer.

P Shanmugam S, Zhou Y, Stelter I, Hanlon T, Bekele R, Bellmunt J Bladder Cancer. 2025; 11(1):23523735251317865.

PMID: 40034244 PMC: 11864231. DOI: 10.1177/23523735251317865.

The Tight Relationship Between the Tumoral Microenvironment and Radium-223.

Conte M, Tomaciello M, De Feo M, Frantellizzi V, Marampon F, De Cristofaro F Biomedicines. 2025; 13(2).

PMID: 40002869 PMC: 11853176. DOI: 10.3390/biomedicines13020456.

Prp19/CDC5L promotes gastric cancer via activation of the MAPK pathway-mediated homologous recombination.

Qiu S, Wang F, Gao X, Guan W, Dai T, Yin L Int J Biol Sci. 2025; 21(4):1603-1618.

PMID: 39990666 PMC: 11844288. DOI: 10.7150/ijbs.101962.

Targeting Ataxia Telangiectasia-Mutated and Rad3-Related for Anaplastic Thyroid Cancer.

Lin S, Hsueh C, Chen W, Chou T, Wong R Cancers (Basel). 2025; 17(3).

PMID: 39941729 PMC: 11816221. DOI: 10.3390/cancers17030359.

References

Chera B, Sheth S, Patel S, Goldin D, Douglas K, Green R . Phase 1 trial of adavosertib (AZD1775) in combination with concurrent radiation and cisplatin for intermediate-risk and high-risk head and neck squamous cell carcinoma. Cancer. 2021; 127(23):4447-4454. DOI: 10.1002/cncr.33789. View

De Vos M, Schreiber V, Dantzer F . The diverse roles and clinical relevance of PARPs in DNA damage repair: current state of the art. Biochem Pharmacol. 2012; 84(2):137-46. DOI: 10.1016/j.bcp.2012.03.018. View

Esteller M, Silva J, Dominguez G, Bonilla F, Matias-Guiu X, Lerma E . Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst. 2000; 92(7):564-9. DOI: 10.1093/jnci/92.7.564. View

Yap T, OCarrigan B, Penney M, Lim J, Brown J, De Miguel Luken M . Phase I Trial of First-in-Class ATR Inhibitor M6620 (VX-970) as Monotherapy or in Combination With Carboplatin in Patients With Advanced Solid Tumors. J Clin Oncol. 2020; 38(27):3195-3204. PMC: 7499606. DOI: 10.1200/JCO.19.02404. View

Sanjiv K, Hagenkort A, Calderon-Montano J, Koolmeister T, Reaper P, Mortusewicz O . Cancer-Specific Synthetic Lethality between ATR and CHK1 Kinase Activities. Cell Rep. 2016; 14(2):298-309. PMC: 4713868. DOI: 10.1016/j.celrep.2015.12.032. View

Scott D, Coyne A, Venkitaraman A, Blundell T, Abell C, Hyvonen M . Small-molecule inhibitors that target protein-protein interactions in the RAD51 family of recombinases. ChemMedChem. 2014; 10(2):296-303. PMC: 4506530. DOI: 10.1002/cmdc.201402428. View

Bock F, Chang P . New directions in poly(ADP-ribose) polymerase biology. FEBS J. 2016; 283(22):4017-4031. DOI: 10.1111/febs.13737. View

Hong D, Infante J, Janku F, Jones S, Nguyen L, Burris H . Phase I Study of LY2606368, a Checkpoint Kinase 1 Inhibitor, in Patients With Advanced Cancer. J Clin Oncol. 2016; 34(15):1764-71. PMC: 5321045. DOI: 10.1200/JCO.2015.64.5788. View

Kaye S . Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol. 2016; 27 Suppl 1:i1-i3. PMC: 4852273. DOI: 10.1093/annonc/mdw082. View

10.

Frit P, Barboule N, Yuan Y, Gomez D, Calsou P . Alternative end-joining pathway(s): bricolage at DNA breaks. DNA Repair (Amst). 2014; 17:81-97. DOI: 10.1016/j.dnarep.2014.02.007. View

11.

Stracker T, Usui T, Petrini J . Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair (Amst). 2009; 8(9):1047-54. PMC: 2725228. DOI: 10.1016/j.dnarep.2009.04.012. View

12.

Gordon M, Rosen L, Mendelson D, Ramanathan R, Goldman J, Liu L . A phase 1 study of TRC102, an inhibitor of base excision repair, and pemetrexed in patients with advanced solid tumors. Invest New Drugs. 2012; 31(3):714-23. PMC: 6662598. DOI: 10.1007/s10637-012-9876-9. View

13.

Oza A, Estevez-Diz M, Grischke E, Hall M, Marme F, Provencher D . A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive -mutant Ovarian Cancer. Clin Cancer Res. 2020; 26(18):4767-4776. DOI: 10.1158/1078-0432.CCR-20-0219. View

14.

Murai J, Huang S, Das B, Renaud A, Zhang Y, Doroshow J . Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors. Cancer Res. 2012; 72(21):5588-99. PMC: 3528345. DOI: 10.1158/0008-5472.CAN-12-2753. View

15.

Hanahan D, Weinberg R . Hallmarks of cancer: the next generation. Cell. 2011; 144(5):646-74. DOI: 10.1016/j.cell.2011.02.013. View

16.

Matsuoka S, Ballif B, Smogorzewska A, McDonald 3rd E, Hurov K, Luo J . ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316(5828):1160-6. DOI: 10.1126/science.1140321. View

17.

Helleday T . The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011; 5(4):387-93. PMC: 5528309. DOI: 10.1016/j.molonc.2011.07.001. View

18.

Bang Y, Im S, Lee K, Cho J, Song E, Lee K . Randomized, Double-Blind Phase II Trial With Prospective Classification by ATM Protein Level to Evaluate the Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients With Recurrent or Metastatic Gastric Cancer. J Clin Oncol. 2015; 33(33):3858-65. DOI: 10.1200/JCO.2014.60.0320. View

19.

Hickson I, Zhao Y, Richardson C, Green S, Martin N, Orr A . Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res. 2004; 64(24):9152-9. DOI: 10.1158/0008-5472.CAN-04-2727. View

20.

Huber K, Salah E, Radic B, Gridling M, Elkins J, Stukalov A . Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014; 508(7495):222-7. PMC: 4150021. DOI: 10.1038/nature13194. View